Smartpatient, Novo Nordisk launch digital diabetes support in Germany

Smartpatient and Novo Nordisk have launched a digital support program for people with Type 2 diabetes in Germany, extending their direct-to-patient model beyond obesity care. The move aims to improve treatment engagement between doctor visits, when long-term habits and drop-off risk are most likely to form.

Why it matters: - The new program gives people with Type 2 diabetes in Germany additional support beyond clinic visits. - The collaboration extends a direct-to-patient model beyond obesity care into another major metabolic disease. - The companies are betting that better support between appointments can improve long-term treatment continuity and reduce treatment discontinuation. - The program treats continuous patient support as a core part of metabolic disease management, not an add-on.

What happened: - Smartpatient and Novo Nordisk launched a digital support program for people living with Type 2 diabetes in Germany. - The initiative expands a direct-to-patient model that was first developed for obesity care. - The program is delivered through MyTherapy, a medication management platform with more than 12 million users worldwide. - The rollout gives the companies a shared digital infrastructure for supporting people with metabolic diseases.

The details: - The program supports patients from treatment initiation through long-term management. - The support package includes personalized onboarding journeys, treatment guidance, contextual educational content, refill and appointment support, symptom and health tracking, and behavior-based engagement tools. - Smartpatient says the system is built around real-world patient needs and treatment journeys. - Novo Nordisk says the collaboration is meant to help patients manage therapy with greater confidence and continuity over the long term. - Smartpatient says the approach is designed to support patients consistently between clinical interactions, where long-term treatment behaviors are formed. - Smartpatient is part of Redcare Pharmacy Group and provides direct-to-patient solutions for the pharmaceutical industry. - Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Denmark. - Novo Nordisk employs about 77,400 people in 80 countries and markets products in around 170 countries.

Between the lines: - The launch reflects a broader push in chronic care to connect medication support, education and engagement in one digital flow. - The model could help pharmaceutical companies stay involved in day-to-day disease management without replacing healthcare professionals. - The focus on adherence, refill support and symptom tracking suggests the companies see behavior change as a major barrier in metabolic care. - The partnership also signals that direct-to-patient tools are moving from a single-condition use case toward a wider platform strategy.

What's next: - Smartpatient and Novo Nordisk are positioning additional continuous patient support as a standard part of metabolic disease management. - The companies will likely use the German Type 2 diabetes program to deepen their connected-care model over time. - The broader MyTherapy ecosystem may become a larger channel for future patient support programs in chronic disease.

The bottom line: - Smartpatient and Novo Nordisk are turning digital support into a long-term care layer for metabolic disease, starting with Type 2 diabetes in Germany.